Cercar
01/06/2024
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
Gately, L, Mesía, C, Sepúlveda, JM, del Barco, S, Pineda, E, Gironés, R, Fuster, J, Dumas, M, Gill, S, Navarro, LM, Herrero, A, Dowling, A, de las Peñas, R, Vaz, MA, Alonso, M, Lwin, Z, Harrup, R, Peralta, S, Long, A, Perez-Segura, P, Ahern, E, Garate, CO, Wong, M, Campbell, R, Cuff, K, Jennens, R, Gallego, O, Underhill, C, Martinez-Garcia, M, Covela, M, Cooper, A, Brown, S, Rosenthal, M, Torres, J, Collins, IM, Gibbs, P, Balana, C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2)DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3.100(Q2/4D).
01/06/2024
Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies
Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study
Serda, PC, Cullell, BM, Castet, F, Gatell, AP, Fernandez, PR, Fernandez, J, Nadal, TS, Mateo, FJP, Sorolla, MA, Cajal, TRY. Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/annonc.2024.05.508. PMID:. IF:65.400(Q1/1D).
01/06/2024
Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study
Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024)
Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).
01/06/2024
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)
Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).